Catherine Owen Adams is Chief Executive Officer of Acadia Pharmaceuticals Inc (ACAD). The company reported total compensation of $8,256,518 for fiscal year 2025.
| Salary | $930,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $3,240,558 |
| Option awards | $3,234,797 |
| Non-equity incentive plan | $818,559 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $32,604 |
| Total | $8,256,518 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Acadia Pharmaceuticals Inc filed April 24, 2026, accession 0001193125-26-174163.
| Peer-group chief executive median | $11,297,184 |
|---|---|
| Difference from that median | $-3,040,666 |
| Percentile within the disclosed peer group | 28th |
| Peers with a disclosed figure | 17 |
Medians and percentiles are computed across the peer group Acadia Pharmaceuticals Inc discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Catherine Owen Adams this page | Chief Executive Officer | $8,256,518 |
| Mark Schneyer | Executive Vice President, Chief Financial Officer | $3,119,408 |
| Jennifer Rhodes | Executive Vice President, Chief Legal Officer and Secretary | $2,927,897 |
| Elizabeth Thompson | Executive Vice President, Head of Research and Development | $2,888,383 |
| Thomas Garner | Executive Vice President, Chief Commercial Officer | $857,023 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Acadia Pharmaceuticals Inc compensation brief.
Catherine Owen Adams's compensation sits inside Acadia Pharmaceuticals Inc's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.